Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|NG-641||NG 641|NG641||NG-641 is an engineered oncolytic enadenotucirev adenovirus expressing a bispecific FAP-TAc T-cell activator that binds to fibroblast activating protein (FAP) on cancer associated fibroblasts and to CD3 on T-lymphocytes, as well as CXCL9, CXCL10, and IFN alpha, which potentially enhances T-cell activation and induces killing of FAP-positive tumor fibroblasts (Cancer Res 2019;79(13 Suppl):Abstract nr 5013).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04053283||Phase I||NG-641||First in Human Study With NG-641, an Oncolytic Transgene Expressing Adenoviral Vector||Recruiting||USA||0|
|NCT04830592||Phase I||NG-641 NG-641 + Pembrolizumab||A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck (MOAT)||Recruiting||1|